MAFA
BIO icon

MJT & Associates Financial Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

MJT & Associates Financial Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-6
Closed -$1.76K – 445
2026
Q2 		$1.76K Buy
+6
New +$1.7K ﹤0.01% 394

Other funds holding BIO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
SGH
Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
FRA
Frank Rimerman Advisors Palo Alto, California $1.81B AUM 32.96% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Blue Trust Inc
Blue Trust Inc Alpharetta, Georgia $9.51B AUM 13.02% 1-Year Est. Return

MJT & Associates Financial Advisory's BIO Position: Q3 2026 in Review

MJT & Associates Financial Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2026, closing a stake of 6 shares — an estimated $1.76K sold.

MJT & Associates Financial Advisory first reported a position in BIO in Q2 2026 and held it in 1 quarter. The position peaked at $1.76K in Q2 2026. 37 funds tracked by Wall St. Rank hold BIO as of Q3 2026.

  • MJT & Associates Financial Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q3 2026 after selling out during the quarter.
  • MJT & Associates Financial Advisory sold 6 Bio-Rad Laboratories Class A shares in Q3 2026, an estimated $1.76K.
  • MJT & Associates Financial Advisory first reported a position in Bio-Rad Laboratories Class A in Q2 2026 and held it in 1 quarter.
  • MJT & Associates Financial Advisory's Bio-Rad Laboratories Class A position peaked at $1.76K in Q2 2026.
  • 37 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q3 2026, filed 7 Oct 2026.